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VlsE is a 35-kDa surface-exposed lipoprotein of Borrelia burgdorferi that was shown previously to undergo
antigenic variation through segmental recombination of silent vls cassettes with vlsE during experimental
mouse infections. Previous data had indicated that sera from North American Lyme disease patients and
experimentally infected animals contained antibodies reactive with VlsE. In this study, sera from patients with
Lyme disease, syphilis, and autoimmune conditions as well as from healthy controls were examined for
reactivity with VlsE by Western blotting and enzyme-linked immunosorbent assay (ELISA). Strong Western
blot reactivity to a recombinant VlsE cassette region protein was obtained consistently with Lyme disease sera.
Although sera from Lyme disease patients also reacted with a band corresponding to VlsE in B. burgdorferi
B31-5A3, interpretation was complicated by low levels of VlsE expression in in vitro-cultured B. burgdorferi and
by the presence of comigrating bands. An ELISA using recombinant VlsE was compared with an ELISA using
sonically disrupted B. burgdorferi as the antigen. For a total of 93 Lyme disease patient sera examined, the VlsE
ELISA yielded sensitivities of 63% for culture-confirmed erythema migrans cases and 92% for later stages, as
compared to 61 and 98%, respectively, for the “whole-cell” ELISA. The specificities of the two assays with
healthy blood donor sera were comparable, but the VlsE ELISA was 90% specific with sera from syphilis
patients, compared to 20% specificity for the whole-cell ELISA with this group. Neither assay showed reactivity
with a panel of sera from 20 non-Lyme disease arthritis patients or 20 systemic lupus erythematosus patients.
Our results indicate that VlsE may be useful in the immunodiagnosis of Lyme disease and may offer greater
specificity than ELISAs using whole B. burgdorferi as the antigen.
Lyme disease, a systemic disease caused by members of the
spirochetal genus Borrelia, is an important emerging infection
in the United States, Europe, and other areas. Ninety-one
percent of the vector-borne infections that are currently re-
ported to the Centers for Disease Control and Prevention are
caused by Borrelia burgdorferi (4, 5). Manifestations include the
appearance of localized erythema migrans (EM) and flu-like
ailments in the very early stages of the disease, which can
progress to multifocal EM, cardiac disease, severe arthritis,
and various neurological symptoms in untreated cases (13, 17).
Clinical diagnosis of Lyme disease can be problematic when
a patient does not present with EM. In these cases, diagnosis
relies on laboratory diagnostic tests. Current tests include iso-
lation and culture of the causative agent (1, 16, 21), PCR to
detect Borrelia DNA (2, 12, 18), and a “two-tiered system” for
the detection of antibodies using enzyme-linked immunosor-
bent assays (ELISA) and Western blots (3, 5). Each of these
current tests has constraints that limit the reliability of its
results, and a standardized serological test that would improve
sensitivity and specificity and detect early disease would be
beneficial to patient diagnosis. In addition, ELISA utilizing
whole B. burgdorferi as the antigen yield false-positive reactions
for individuals vaccinated with recombinant OspA (19, 20),
driving the development of immunoassays using recombinant
B. burgdorferi antigens (11) or variants of B. burgdorferi defi-
cient in OspA and OspB expression (25).
VlsE (Vmp-like sequence) is a 35-kDa lipoprotein that un-
dergoes antigenic variation and is thought to play a major role
in the immune response against Lyme disease borreliae (22).
The vls locus of B. burgdorferi B31 is located on a 28-kb linear
plasmid (lp28-1) and consists of an expression site (vlsE) and
15 silent vls cassettes (Fig. 1). The silent cassettes have high
homology to the central, cassette region of the vlsE expression
site, showing 90.0 to 96.1% nucleotide sequence identity and
76.9 to 91.4% predicted amino acid sequence identity to the
vlsE1 cassette. The cassettes are demarcated by 17-bp direct
repeats at either end. Within each cassette, there are six vari-
able regions interspersed between highly conserved regions
(22).
Recombination of apparently randomly selected segments of
the silent cassettes with homologous regions of vlsE has been
shown to occur within 4 days of experimental infection of mice
with B. burgdorferi B31 and continues throughout the course of
infection (24). These recombination events appear to involve
gene conversion, leading to changes in the sequence of the
expression cassette (vlsE1) but no changes in the sequences of
the silent cassettes (23). The resulting B31 variants exhibit
decreased reactivity to antisera raised against a recombinant
form of the vlsE cassette region from the parental clone; this
finding indicates that the sequence changes result in antigenic
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variation (22). The persistent infection seen in Lyme disease
patients may be in part a result of this antigenic variation.
An unexpected finding in initial VlsE studies was that in-
fected mice (either needle or tick inoculated) and Lyme dis-
ease patients developed strong antibody responses against
VlsE (22). This reactivity, detected by Western blotting, was
thought to be directed against the conserved regions of the
VlsE protein. In the present study, Western blot and ELISA
procedures were developed and used to examine the occur-
rence of anti-VlsE antibodies in Lyme disease patients at var-
ious stages of infection.
MATERIALS AND METHODS
Bacterial strains and plasmids. B. burgdorferi B31 was initially isolated from
Ixodes scapularis and was cultured in BSK II medium (15). B31-5A3 is a low-
passage-number clone that has retained its ability to cause disease in C3H/HeN
mice and harbors the VlsE-encoding linear plasmid, lp28-1. B31-5A2 is a low-
passage-number clone that has low infectivity in mice and lacks lp28-1 (15, 22).
Escherichia coli BL-21(DE3) (Novagen, Madison, Wis.) and E. coli SURE2
(Stratagene, La Jolla, Calif.) were used for recombinant protein expression.
Plasmids pGEX-2T (Pharmacia Biotech Inc., Piscataway, N.J.) and pQE30 (Qia-
gen, Santa Clarita, Calif.) were used for expression of glutathione S-transferase
(GST) and polyhistidine fusion proteins, respectively.
Human sera. Human sera from Lyme disease patients were obtained from the
Marshfield Laboratory of Wisconsin, the New York Medical College in Valhalla,
N.Y., the New England Medical Center in Boston, Mass., and the Centers for
Disease Control and Prevention in Fort Collins, Colo. The samples from the
Centers for Disease Control were acquired between 8 days and 2.8 years post-
treatment (median, 64 days), whereas the samples from other sources were
obtained at the time of presentation. A panel of serum samples from patients
with primary, secondary, early latent, or late latent syphilis was acquired from the
City of Houston Health Department. Serum specimens from non-Lyme arthritis
patients were obtained from a serum bank maintained by A.C.S. at the New
England Medical Center. Serum samples from patients with systemic lupus
erythematosus (SLE) were graciously provided by F.C. Arnett of the University
of Texas Health Science Center at Houston. Normal human sera from a region
FIG. 1. (A) Arrangement of vlsE and silent cassettes in vls locus of B. burgdorferi B31-5A3 (16). (B) Depiction of recombinational events that occur between the
vlsE expression site and silent cassettes. (C) VlsE fusion constructs used in this study.










where borreliosis is not endemic were obtained from volunteers at the University
of Texas Health Science Center at Houston and the Gulf Coast Blood Center in
Houston, Tex. A positive serum pool consisting of five Lyme disease sera from
the Marshfield Laboratory and a normal pool consisting of three normal sera
from Houston, Tex., were used in standardization procedures.
Serum samples from Lyme disease patients were subdivided into four groups
based on the stage of disease. Group 1 represented culture-positive EM patients
(41 patients). These patients were in early stages of disease with typical EM
lesions, and B. burgdorferi was cultured from skin biopsy or blood samples from
the patients. Group 2 consisted of patients with early disseminated disease (12
patients). Patients had EM lesions accompanied by secondary annular skin le-
sions, headache, neck stiffness, atrioventricular nodal block, or migratory mus-
culoskeletal pain, occurring weeks after the onset of infection. Patients in group
3, acute neuroborreliosis (17 patients), had meningitis, facial palsy, or radiculo-
neuritis, occurring weeks to months after the onset of infection. Group 4, Lyme
arthritis (23 patients), had oligoarticular arthritis, most commonly affecting the
knees, occurring months to years after the disease onset.
Recombinant VlsE protein. The 614-bp vlsE cassette region of B31-5A3 was
amplified by PCR and expressed as a GST fusion protein (VlsE1–GST) as
described previously (Fig. 1) (22). Recombinant GST expressed from pGEX-2T
without an insert was used as a control.
To obtain a recombinant protein corresponding to the full-length, mature
VlsE, the vlsE locus of B31-5A3 (GenBank accession no. U76405) was amplified
by PCR from borrelial plasmid preparations as described previously (22) using
the plus-strand primer F4120 (59-CGGGGATCCAGCCAAGTTGCTGATAA
GGACGACCC-39) and the minus-strand primer R4121 (59-CGGAAGCTTCA
ATCATGAGGGCATAGTCGTGTCCATACA-39). The resulting amplification
product began at nucleotide 63 of the open reading frame (just after the cleavage
site of the signal peptide) and continued past the stop codon of the gene; it was
1,227 bp in length. The underlined regions denote recognition sequences for
BamHI in the plus-strand primer and HindIII in the minus-strand primer. The
fragment was treated with BamHI and HindIII, purified, and then ligated into a
BamHI–HindIII-treated pQE30 vector, which contains a sequence encoding an
N-terminal His6 tag (Fig. 1). The resultant recombinant plasmid (pVlsE1–His3)
was transformed into E. coli SURE2.
Purification of recombinant VlsE protein. The GST-VlsE1c fusion protein was
expressed in E. coli BL-21(DE3) and purified by using a glutathione-Sepharose
4B column (Pharmacia Biotech Inc.) as described by the manufacturer. For the
VlsE1–His fusion construct, six 1-liter SURE2/pVlsE1-His3 cultures in Luria-
Bertani medium were inoculated from overnight cultures and incubated at 37°C
for 2.5 h with shaking. Expression of the VlsE1-His fusion protein was induced
by adding isopropyl-b-D-thiogalactopyranoside (IPTG) to a final concentration
of 0.2 mM and incubating the cultures for an additional 3 h. Bacteria were
harvested by centrifugation, the supernatant was decanted, and the cell pellets
were resuspended in phosphate-buffered saline (PBS) and stored at 280°C. The
cell suspension was later thawed, and the cells were lysed by two passages
through a French press. Insoluble cell debris was removed by centrifugation at
28,000 3 g for 20 min, followed by filtration through a 0.45-mm-pore-size mem-
brane. Recombinant VlsE1–His fusion protein was then initially purified by
metal chelating chromatography. Bacterial lysates were applied to an HR10/10
(Pharmacia Biotech Inc.) column of nickel-charged iminodiacetic acid Sepharose
(Sigma Chemical Company, St. Louis, Mo.), and the bound protein was eluted
with a 200-ml linear gradient of 0 to 200 mM imidazole in 4 mM Tris-HCl–100
mM NaCl (pH 7.9) at a flow rate of 2 ml/min. Fractions corresponding to the
VlsE1–His fusion protein, as determined by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE), were pooled and dialyzed against 10
mM phosphate, pH 7.2, before further purification. Dialyzed VlsE1–His fusion
protein was applied to a 1-ml HiTrap heparin-Sepharose column (Pharmacia
Biotech Inc.), and bound protein was eluted with a 40-ml linear gradient of 0 to
0.5 M NaCl in 10 mM phosphate (pH 7.2) at a flow rate of 2 ml/min. Fractions
containing purified VlsE1–His were determined by SDS-PAGE followed by
staining with Coomassie brilliant blue R-250. Buffer exchange (with PBS) and
protein concentration were achieved by using the Centricon Plus-20 filter system
(Millipore, Bedford, Mass.) as described by the manufacturer, and the concen-
tration of the protein was determined by the Bradford assay (Bio-Rad, Hercules,
Calif.).
Western blot analysis. Protein samples were separated by electrophoresis
using SDS-PAGE with a 12% acrylamide gel at a constant voltage of 180 mV.
Each Western blot consisted of lanes containing B31-5A2 and B31-5A3 (106 cells
each), 25 ng of the VlsE1–GST fusion protein, and 25 ng of GST protein. The
immunoblots were processed by the method of Norris et al. (14), with human
serum used as the primary antibody. Detection of reactivity was analyzed by
using ECL Western blotting detection reagents (Amersham International,
Princeton, N.J.) as described by the manufacturer.
ELISA analysis. Ninety-six-well flat-bottom Immulon-2 plates (Dynex Tech-
nologies, Chantilly, Va.) were coated with 100 ml of the indicated dilutions of the
purified VlsE1–His fusion protein or sonically disrupted whole cells in coating
buffer (15 mM Na2CO3–35 mM NaHCO3) overnight at 37°C. Two hundred
microliters of PBS with 1% nonfat dried milk was added to each well, and the
plates were incubated at 37°C for 2 h. Wells were then washed five times with 100
ml of PBS with 0.05% Tween 20 (PBS-Tween). Sixty microliters of the primary
antibody (human sera) diluted in PBS with 1% milk was added to triplicate wells,
and the plates were incubated for 2 h at 37°C. The wells were then washed five
times with 100 ml of PBS-Tween. Alkaline phosphatase-conjugated goat anti-
human immunoglobulin (Ig) (obtained by immunization with purified IgA, IgD,
IgE, IgG, and IgM) (Boehringer Mannheim, Indianapolis, Ind.) (100 ml of a
1:8,000 dilution) was added to each well, and the plates were incubated for 1 h
at 37°C. Wells were then washed 10 times with 100 ml of PBS-Tween. One
hundred microliters of p-nitrophenyl phosphate substrate (Sigma Chemical
Company) diluted to 1 mg/ml in DEA buffer (730 mM diethanolamine, 1 mM
MgCl2, 3 mM sodium azide) was then added to each well, and the plates were
incubated for 30 min at 37°C. Fifty microliters of stop buffer (2 M NaOH) was
added to each well, and the optical density (OD) was read at 405 nm with a
SpectraMAX 250 plate reader (Molecular Dynamics, Sunnyvale, Calif.). Mean
OD values for each sample were normalized by dividing by the mean OD value
of a pooled Lyme disease serum standard obtained in the same ELISA run. Each
serum specimen was tested on at least two separate occasions to ensure repro-
ducibility of results.
RESULTS
Western blot reactivity. In preliminary studies, 16 serum
samples from seropositive patients at various stages of Lyme
disease and 3 serum samples from healthy volunteers were
screened for antibody reactivity to the VlsE cassette region by
Western blot analysis. Blots used in these studies consisted of
lanes for B. burgdorferi clones B31-5A2 and B31-5A3, the re-
combinant VlsE1c-GST fusion protein (Fig. 1C), and GST as a
negative control. All 16 seroreactive samples showed reactivity
with multiple B. burgdorferi proteins of both B31-5A2 and
B31-5A3 (Fig. 2). The location of VlsE, which is present in
B31-5A3 but not in B31-5A2, is indicated in Fig. 2. All Lyme
disease sera tested exhibited increased reactivity in the 45-kDa
region of B31-5A3 relative to that observed in B31-5A2, con-
sistent with the presence of anti-VlsE antibodies. However,
this difference was often obscured by the presence of comi-
grating reactive bands in both B. burgdorferi clones. The Lyme
disease patient sera were also consistently reactive with the
VlsE1c-GST fusion protein, but no reactivity to the GST pro-
tein alone was observed (Fig. 2). The three normal-serum
controls showed no reactivity to the B. burgdorferi proteins or
the VlsE fusion protein (data not shown). These results pro-
FIG. 2. Representative Western blot using serum from a Lyme disease pa-
tient. Lanes correspond to B. burgdorferi B31-5A2 (which lacks VlsE), B31-5A3
(which expresses VlsE), the VlsE1c-GST fusion protein, and GST alone. Arrow
indicates band corresponding to VlsE in B31-5A3.










vided preliminary evidence that an anti-VlsE antibody re-
sponse is raised in Lyme disease patients.
ELISA standardization. Checkerboard titrations of VlsE1–
His and positive- and negative-control serum pools were per-
formed to optimize ELISA conditions. Five sera exhibiting
strong reactivity to VlsE by Western blotting were chosen to
make a positive pool. Three normal serum samples were com-
bined to form a negative-control pool. Ninety-six-well plates
were coated with twofold serial dilutions of the VlsE1–His
fusion protein (0.4 to 0.0125 mg/well). Serial dilutions of the
serum pools were also performed (1:100 to 1:12,800). The
ELISA was performed as described in Materials and Methods.
The absorbance values for the positive- and negative-control
pools of corresponding dilutions were compared. A second
ELISA with a narrowed range of VlsE1–His concentrations
(0.1, 0.075, 0.05, 0.037, and 0.025 mg/well) was then performed,
and the ratios between the absorbency values of the two pools
were examined (Fig. 3). This analysis is a measure of antigen
and serum concentrations that provide the highest “signal-to-
noise” ratio between the positive and negative samples. An
antigen concentration of 50 ng of VlsE1-His/well and a serum
dilution of 1 to 800 had a strong positive-to-negative ratio.
These conditions were used in further screening of human sera
with VlsE1-His.
A similar checkerboard titration was carried out to standard-
ize a concentration of whole-cell proteins for use in ELISA
screening of human sera. Whole-cell B. burgdorferi B31-5A2
and B31-5A3 were lysed by sonication prior to use. Serial
dilutions of the whole-cell preparations (2.4 to 0.0188 mg of
protein/well) and the same dilutions of sera used in the VlsE1–
His ELISA were used in this checkerboard. The ratios between
the positive and control pools determined that a concentration
of whole-cell proteins of 600 ng/well and a serum dilution of 1
to 800 were optimal (data not shown). The results using B31-
5A2 or B31-5A3 as the antigen were essentially identical, and
B31-5A3 was used in all subsequent studies.
Reactivities of individual sera. The optimized conditions for
the VlsE1–His and whole-cell ELISAs were used to test 104
coded serum samples that were obtained from New York Med-
ical College (20 samples), The New England Medical Center
(37 samples), and the Centers for Disease Control and Pre-
vention (47 samples). Fifty normal serum samples obtained
from a region where borreliosis is not endemic (The Gulf
Coast Regional Blood Center, Houston, Texas) were used as
seronegative controls. The ELISA for the coded samples was
performed in a blind fashion. Each sample was tested in trip-
licate in the VlsE1–His ELISA and screened in parallel with
the whole-cell assay. The procedure was repeated to provide a
measure of reproducibility. Results are depicted in Fig. 4 as
averages of the normalized values obtained with the two tests.
The absorbance values were normalized by dividing the OD of
the sample by the OD of the positive pool that was tested on
the same plate. The normalization of the absorbance values
allows for comparative analysis between plates and assays.
Both the VlsE1–His and whole-cell procedures gave an aver-
age normalized OD value of 0.03 for the normal sera that were
tested. Ninety-five percent of the normal samples tested with
VlsE1–His had absorbance values below 0.062, and 99% of the
absorbance values were below 0.075. With the whole-cell
ELISA, 95 and 99% of the samples tested had absorbance
values below 0.082 and 0.107, respectively. The sensitivities of
the VlsE1–His and whole-cell assays were assessed by using the
95 and 99% confidence intervals (CI) for 50 normal serum
samples to establish cutoff values for nonreactive (,95%),
equivocal (95 to 99%), and reactive (.99%) designations.
The VlsE1–His ELISA and whole-cell ELISA provided
comparable results at each stage of Lyme disease, as shown in
Fig. 4 and Table 1. The VlsE1–His and whole-cell assays were
reactive in 63 and 61% of samples from culture-positive EM
patients, respectively (Table 1), in line with previous observa-
tions that antibody responses are not detectable in a high
proportion of EM patients at the time of presentation. Sensi-
tivity in this group was not increased in a separate set of ELISA
using an IgM-specific secondary antibody to test for anti-VlsE
and anti-B. burgdorferi IgM (data not shown). In the group of
serum samples representing later stages of disease, the VlsE1-
His ELISA yielded an overall sensitivity of 92%, compared
with a sensitivity of 98% for the whole-cell assay. There was
86% agreement between the reactive versus nonreactive or
equivocal results obtained with each individual serum in the
two assays, with a nearly equal number of samples being more
reactive in one assay than the other. However, the correspond-
ing absorbance values obtained with the same serum sample by
the two ELISAs tended to vary, providing an r2 value of 0.52.
Specificity in non-Lyme-disease sera. One of the problems
of the current Lyme ELISA products is that patients infected
with other spirochetal agents may have antibodies that will
cross-react with Borrelia antigens, giving false-positive results
(6, 10). To test if there was cross-reactivity of antibodies raised
against Treponema pallidum with VlsE, 20 serum samples from
human syphilis patients were screened by the VlsE1–His and
whole-cell ELISA. Figure 4 and Table 1 show the results of the
two tests. With the VlsE1–His ELISA, 19 of 20 serum samples
(95%) gave either nonreactive or equivocal readings. In con-
trast, 15 of 20 (75%) were reactive by the whole-cell assay.
We also tested for the reactivity of antibodies in serum
samples from patients with non-Lyme arthritis (20 samples)
and SLE (20 samples) with VlsE1–His or the whole-cell B.
burgdorferi antigen. None of these serum samples exhibited
reactivity to VlsE1–His or whole B. burgdorferi in our assay
format (Table 1).
Reproducibility. A concern with diagnostic tests is their abil-
ity to produce consistent, reproducible results each time they
are used. To determine if the VlsE1–His ELISA protocol that
we developed was reproducible, a correlation curve between
the two VlsE1–His ELISA that we performed on each sample
was created (data not shown). An r2 value of 0.9694 was ob-
tained, indicating that the ELISA is highly reproducible.
DISCUSSION
Zhang et al. (22) had shown previously that a Lyme disease
patient, as well as mice infected with B. burgdorferi, mounted
an antibody response that reacted with the VlsE cassette re-
gion. The initial Western blot analysis in this study demon-
strated that all 16 Lyme disease patients tested produced an-
tibodies that reacted with the VlsE cassette region. This
response was observed in all stages of disease, including the
early stages, when antibody responses are not yet fully devel-
oped. A reactive band corresponding to the expected location
of VlsE was present in the lanes containing the VlsE-express-
ing strain B31-5A3 but was absent or decreased in intensity in
the lanes containing B31-5A2, which lacks lp28-1, the plasmid
encoding VlsE (see Fig. 2 for an example). This evidence
indicates that VlsE constitutes a reactive band in Western blots
in which low-passage-number B. burgdorferi is used as an an-
tigen, although it should be noted that lp28-1 is lost rapidly
during in vitro passage (22, 24).
These preliminary results led us to examine ELISA proce-
dures that would permit efficient and quantitative analysis of
patient specimens. Toward this end, a process was developed
for the large-scale production and purification of a polyhisti-










dine-tagged recombinant VlsE1 protein. Two different col-
umns, utilizing nickel affinity and ion exchange properties,
were employed to limit contamination by E. coli proteins and
hence reduce the background reactivity of normal serum spec-
imens. Checkerboard titration of VlsE1-His antigen concen-
trations and serum dilutions in an ELISA format demonstrated
that a Lyme disease serum pool yielded absorbance values that
were consistently 6- to 11-fold higher than those of a normal
FIG. 3. Standardization of ELISA protocol using recombinant VlsE-His as the antigen. (A) ODs at 405 nm (OD405) of varying dilutions of the positive serum pool
and varying VlsE concentrations. (B) OD405 of varying dilutions of the negative-control serum pool and varying VlsE concentrations. (C) Ratio between the OD405 of the
positive pool and the OD405 of its corresponding negative pool used to determine positive to negative ratios. The key shows the serum dilution indicated by each symbol.










serum pool at a broad range of antibody-antigen concentra-
tions. This high ratio indicated that VlsE1–His-based ELISA
should be relatively insensitive to lab-to-lab variability due to
minor procedural differences. The highest positive-to-negative
ratio was observed at 50 ng of VlsE1-His/well and a 1:800
dilution of serum. We also designed a B. burgdorferi whole-cell
ELISA procedure that could be compared directly with the
VlsE1–His system. A similar standardization of a whole-cell
protocol was performed, and a protein concentration of 600
ng/well and a serum dilution of 1:800 gave a positive-to-nega-
tive ratio similar to that seen for the VlsE1–His standardiza-
tion. In the whole cell-assay, similar results were obtained
when B31-5A3 (containing VlsE) and B31-5A2 (lacking VlsE)
were examined. These results may be explained by the expres-
sion of small quantities of VlsE in in vitro-cultured B. burgdor-
feri, limiting the amount of this protein relative to other anti-
gens.
These combinations were utilized in subsequent analyses of
93 well-characterized sera from U.S. Lyme disease patients,
including samples from Westchester County, N.Y., and the
Boston, Mass., area; a Lyme serum panel that the Centers for
Disease Control and Prevention provides to evaluate Lyme
disease testing protocols was also included. The raw absor-
bance values were normalized by using a reactive serum pool
to limit test-to-test variation. Cutoff values corresponding to a
,95% CI (nonreactive), a 95 to 99% CI (equivocal), and a
.99% CI (reactive) of values obtained from the normal serum
samples were chosen for this study. Overall, the VlsE1–His
ELISA and the whole-cell ELISA were comparable. The two
tests produced the same number of nonreactive samples (15
samples) and similar numbers of equivocal samples (four with
the VlsE1–His ELISA, two with the whole-cell ELISA). The
VlsE1–His ELISA sensitivity was roughly equivalent to that of
the whole-cell ELISA for the culture-positive EM patient
FIG. 4. Comparison of the VlsE1–His and whole-cell ELISA procedures for individual serum samples in different disease states. Shaded bars, average value for each
group. Absorb., absorbance.










group (63.4% versus 61%), but was lower for the other Lyme
disease patient groups tested (92 to 100% versus 96 to 100%)
due to the slightly higher number of equivocal and nonreactive
results in the VlsE1–His ELISA (Table 1).
The VlsE1–His ELISA was much more specific than the
whole-cell assay with regard to the reactivity of syphilitic pa-
tient sera. The absorbances obtained for syphilitic patient sera
and normal sera in the VlsE1-His ELISA were comparable,
whereas 75% of the syphilis sera yielded false-positive reac-
tions in the whole-cell ELISA (Fig. 4; Table 1). The false-
positive reactivity in the whole-cell assay is most likely due to
the presence of flagella and other antigens which cross-react
with anti-T. pallidum antibodies.
The sequence of the recombinant VlsE used in this assay was
derived from a single variant from B. burgdorferi clone B31-
5A3. The discovery that the antibodies reactive with this form
of VlsE could be detected in the majority of sera from Lyme
disease patients that were tested was surprising, considering
that this protein has been shown to undergo antigenic variation
by an elaborate genetic mechanism (22–24). However, the se-
quence changes that take place are confined to certain variable
regions that are separated by six nonvariable or conserved
regions (23). These conserved segments, or the conserved re-
gions found outside the cassette region, could contain the
epitopes recognized by VlsE-reactive antibodies. Liang et al.
reported recently that a synthetic peptide based on the VlsE
invariant region 6 (between variable regions 5 and 6; see Fig. 1)
of B. garinii Ip90 contains an epitope that reacts consistently
with Lyme disease patient serum antibodies (8, 9). All of the
Lyme disease sera analyzed in our study were obtained from
patients from the northeastern and northern United States
who were presumably infected with B. burgdorferi sensu stricto.
We are currently examining vlsE sequences from several B.
burgdorferi, B. garinii, and B. afzelii strains to determine the
degree of interspecies sequence (and antigenic) heterogeneity
that exists.
Preliminary studies indicate that immunization of mice with
recombinant VlsE1–His provides full protection against infec-
tion with B. burgdorferi B31-5A3 but is only partially protective
against B31-5A3 progeny expressing variants of VlsE (7, 7a).
Also, Liang et al. (8) found that antibodies against the invari-
ant region 6 peptide were not borreliacidal, and they hypoth-
esized that this region may not be accessible to antibody in
intact organisms. Taken together, these results suggest that
VlsE invariant regions generate antibody responses potentially
useful for immunodiagnosis but that protective responses tar-
get the variable regions.
In summary, VlsE shows promise as an immunodiagnostic
reagent to aid in the diagnosis of Lyme disease. In the samples
tested in this study, the VlsE1–His ELISA exhibited slightly
lower sensitivity than a whole-cell ELISA. Part of this lower
sensitivity could be due to diminution of antibody in some
posttreatment samples included in this study. VlsE may be
combined with other recombinant antigens in immunoassays
(11). Such assays would not only have lower false-positive rates
for individuals with previous exposure to syphilis or other spi-
rochetal infections but would also overcome the inherent re-
activity of antibodies from OspA-vaccinated individuals in im-
munoassays using OspA-expressing B. burgdorferi as an
antigen.
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